2seventy bio has announced strategic collaboration with JW Therapeutics to accelerate research and development of T cell-based immunotherapies.
Under the alliance, the companies will establish a translational and clinical cell therapy platform to rapidly analyze such immunotherapy products in mainland China, Hong Kong (China) and Macau (China).
The partnership will initially focus on 2seventy bio’s MAGE-A4 TCR program in solid tumors.
This program is currently being developed in partnership with Regeneron.
It is intended to develop T-cell receptor (TCR) therapies for the treatment of MAGE-A4 positive solid tumors.
MAGE-A4 is part of the MAGE family of testicular cancer antigens expressed in various types of solid tumors.
Under the deal, JW Therapeutics will receive a license from 2seventy for the MAGE-A4 cell therapy in partner regions.
In China, JW Therapeutics will oversee the development, manufacturing and marketing of the therapy.
In addition, 2seventy is entitled to receive principal payments and royalties on product revenue in China.
The company may also use the results of initial clinical trials generated under the partnership to support development in other regions.
2seventy and JW Therapeutics have not disclosed details of the alliance.
2seventy bio Chief Medical Officer Steve Bernstein said: “The real patient benefit of this collaboration lies in the ability to create additional opportunities to rapidly test, learn and advance our innovative cell therapy programs.
“JW Therapeutics possesses an extensive understanding of the unmet medical needs of the population and the regulatory affairs process in China, as well as clinical development pathways.
“The opportunity to bring together our distinctive areas of expertise to create a differentiated platform supports our goal of bringing new therapies to patients as quickly as possible.”
Cell and gene therapy coverage for pharmaceutical technologies is supported by Cytiva.
Editorial content is independently created and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Optimize the cell therapy process: a guide to thawing cells
Commonly made at the point of care, errors in cell therapy thawing can compromise treatment efficacy, resulting in significant patient impact as well as high costs and a compromised reputation for the product developer. This guide examines how cell thawing has evolved historically into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from the scientific literature and consideration of interactions between cooling and warming rates applicable to cell and gene therapies.
by Cytiva Thematic
By clicking the Download Free White Paper button, you accept the terms and conditions and confirm that your data will be used as described in Cytiva’s Topical Privacy Policy. By downloading this white paper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information about their products and services.
Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can unsubscribe from future marketing communications. Our Services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
https://www.pharmaceutical-technology.com/news/2seventy-jw-therapeutics-immunotherapies/
